| INTRODUC TI ON
Helicobacter pylori infects approximately half the world's population and one-third of the US population 1 and can lead to peptic ulcer and gastric cancer. Clarithromycin is typically part of first-line treatment along with amoxicillin and a proton-pump inhibitor (PPI). 2 Eradication of H. pylori infection is effective in resolving gastric and duodenal ulcers, 3 gastric MALT lymphomas, 4, 5 and in reducing progression of some preneoplastic lesions to gastric cancer. 6, 7 However, rising rates of antibiotic resistance have negatively impacted the efficacy of H. pylori treatment. 2 Helicobacter pylori infection can be diagnosed by histologic analysis of formalin-fixed gastric biopsy specimens collected during upper GI endoscopy. Formalin fixation precludes bacterial culture, and separate gastric biopsies for culture are rarely collected. Thus, antibiotic resistance testing is generally not performed before prescribing H. pylori treatment, leaving clinicians to rely on empiric treatment strategies, as local patterns of antibiotic resistance are often unknown. Current guidelines recommend against the use of standard triple therapy (clarithromycin, amoxicillin, and PPI) as firstline treatment when the local clarithromycin resistance rate exceeds 20%. 8 If empiric first-and second-line treatments fail to eradicate infection, patients may need to undergo repeat endoscopy, with biopsies collected for culture and antibiotic susceptibility testing, to guide further treatment. 2 Accordingly, a culture-free method to detect antibiotic resistance would be useful for determining resistance patterns in a population and for tailoring the treatment of individual patients. Recently, we reported the use of droplet digital PCR (ddPCR) to quantitatively detect the H. pylori 16S gene and distinguish between alleles of the cagA virulence gene from stool samples. 9 ddPCR provides absolute quantitation and increased sensitivity for detecting rare targets by partitioning the PCR reaction into 10 000-100 000 droplets, and multiple fluorescent hydrolysis probes can differentiate alleles of a given gene. 10 To assess H. pylori antibiotic resistance, we developed a ddPCR assay to detect mutations that confer resistance to clarithromycin. Clarithromycin blocks bacterial protein synthesis by targeting the bacterial 23S ribosomal subunit; however, resistance can arise from point mutations in the 23S rRNA gene. The majority of clarithromycin-resistant H. pylori strains have one of three point mutations (A2142G, A2142C, and A2143G) in the 23S rRNA gene.
11,12
The ddPCR assay we developed uses multiple fluorescent probes to distinguish between the wild-type and the three common clarithromycin resistance 23S rRNA alleles, and quantifies the proportion of 23S rRNA gene copies in a sample with resistance mutations. This assay utilizes DNA extracted from archived, formalin-fixed paraffinembedded (FFPE) gastric tissue samples, eliminating the need for H. pylori bacterial culture. The technique allows for retrospective examination of resistance rates in the population to inform empiric treatment, reported here for patients at University of Washington Medical Center in Seattle, Washington. Additionally, this culturefree assay can also be used for making tailored treatment decisions for individual patients either at the time of initial upper GI endoscopy or to avoid repeat endoscopy in the event of treatment failure.
| MATERIAL S AND ME THODS

| Study populations and specimen collection
Helicobacter pylori-positive gastric biopsy specimens were retrospectively identified from the University of Washington Medical
Center using Current Procedural Terminology (CPT) billing codes.
Chart review was performed to confirm diagnosis of H. pylori infection by histologic analysis using immunofluorescence or Genta stain and identify patients with culture-based antibiotic susceptibility test results.
In total, 146 formalin-fixed, paraffin-embedded (FFPE) gastric biopsy specimens, collected between 2012 and 2014, were identified.
Of these, 28 were determined to have an insufficient amount of remaining tissue to be used in the study. (Table S1 ) into pCR2.1-TOPO plasmid (Invitrogen). The resulting plasmid was used for site-directed mutagenesis using primers A2142G and A2142C (Table S1 ). The mutated plasmids were naturally transformed into G27. 14 Mutant clones were selected by plating on horse blood agar plates containing 0.1 μg/mL clarithromycin followed by PCR and DNA sequencing for confirmation.
| Ethics statement
Mouse studies were performed under practices and procedures of 
| Processing of mouse stomachs H. pylori 23S rRNA gene polymorphism detection
Mouse stomachs were incubated in either liquid H. pylori culture or sterile media for control. Fresh stomach tissues were harvested from uninfected C57BL/6 mice, opened along the lesser curvature, and divided into half. Approximately, 10 7 CFU wild-type H. pylori, 23S
rRNA mutant H. pylori, or a mixture of wild-type and mutant bacteria in 100 μL BB10 (Brucella broth (BD Biosciences), supplemented with 10% fetal bovine serum (GIBCO), or 100 μL sterile BB10 were added to the luminal side of each half stomach and incubated for 30 minutes in a tri-gas incubator before fixation in 10% buffered formalin phosphate (Fisher). After fixation, the half-stomachs were embedded in paraffin by FHCRC Experimental Histopathology Shared
Resource and five 10 μm curls were cut from each block for DNA extraction.
| Primer and probe design
The primer and probe sequences for the H. pylori 23S rRNA gene and human 18S rRNA gene ddPCR assays are listed in Table S1 .
Probes were designed to distinguish between the H. pylori wildtype 23S rRNA allele and the three most common clarithromycin resistance-conferring mutations in the H. pylori 23S rRNA gene (A2143G, A2142G, and A2142C). The wild-type probe was labeled with hexachloro-fluorescein (HEX), and the three clarithromycin resistance mutation probes were labeled with 6-carboxyfluorescein (FAM). All four probes were included in a single reaction. For quantification of human DNA, a single HEX probe to the wild-type human 18S rRNA gene was utilized.
| DNA extraction and droplet digital PCR
DNA was extracted from curls of FFPE gastric tissue using the FFPE 
| Statistical analysis
Age, sex, and race were compared between patients with clarithromycin resistance alleles and patients with only wild-type allele by Student's t test or chi-square test, as appropriate. Copy number of the 23S rRNA gene between racial groups was compared using the Wilcoxon rank-sum test. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc.).
| RE SULTS
| Droplet digital PCR is more sensitive than Sanger sequencing for detection of H. pylori 23S clarithromycin resistance alleles
To assess the sensitivity of the H. pylori 23S rRNA clarithromycin resistance ddPCR assay to detect and quantify clarithromy-
cin resistance alleles, we tested the assay on genomic DNA from a clarithromycin-sensitive wild-type strain and three isogenic clarithromycin-resistant strains spiked into water individually and in different ratios. The clarithromycin resistance ddPCR assay correctly distinguished between wild-type and resistance alleles. The assay also correctly quantified the ratios of wild-type and resistance alleles for all ratios that were tested, and it detected resistance mutations even when present in just 1% of the H. pylori DNA ( Figure 1A ).
In comparison, Sanger sequencing of 23S rRNA gene PCR product, which is often used for genotypic testing of H. pylori clarithromycin resistance, was only able to detect a mixture of wild-type and resistance alleles at a 1:1 ratio ( Figure 1B ). Table 1 .
| Detection and quantification of
Of these 110 patients, the 23S rRNA gene was detected by ddPCR (Table 1) . Of those with a mix of wildtype and resistance alleles, the percent of 23S rRNA gene copies having a resistance mutation ranged from 0.02% to 99.7% with a median of 13%.
| Prevalence of clarithromycin resistance alleles varied by race and was highest among Asian patients
Age and sex were not significantly different between patients with clarithromycin resistance alleles and patients with only wild-type alleles. While the prevalence of clarithromycin resistance was above 20% in all racial groups, a significantly higher proportion of Asian patients had clarithromycin resistance alleles compared to non-Asian patients. Of the 21 Asian patients, 14 (67%) had clarithromycin resistance alleles compared to 31 (38%) of the 81 non-Asian patients (chi-square, P = .02; Table 2 ).
Since the limit of detection of clarithromycin resistance alleles depends on H. pylori 23S rRNA gene copy number, differences in H. pylori load among racial groups could contribute to differences in the proportion of patients with clarithromycin resistance alleles detected. However, the 23S rRNA gene copy number was not 
| D ISCUSS I ON
We have developed a ddPCR assay for detecting H. pylori clarithromycin resistance alleles in FFPE gastric tissue samples which can be used retrospectively to examine the prevalence of clarithromycin resistance in a population or to detect resistance in an individual patient to inform treatment. The prevalence of clarithromycin resistance among patients at a Northwestern US hospital as measured by F I G U R E 3 Detection of H. pylori 23S rRNA gene by ddPCR does not depend on the amount of gastric tissue in formalin-fixed paraffin-embedded (FFPE) samples measured by human 18S rDNA gene. The human 18S rDNA gene concentration (copies per μL) was compared for four samples with no H. pylori 23S rRNA gene detected and four samples each in the lowest, middle, and highest third of 23S rRNA gene copy number. The median for each group is indicated by a horizontal line 
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